Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications

Biomarker Research

Review

Mengping Chen¹  Jinxing Jiang¹  Jian Hou¹ 

[1] Department of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, 200127, Shanghai, China;

关键词: Multiple myeloma;    Single-cell sequencing;    Tumor heterogeneity;    Tumor microenvironment;    Clinical translation;   

DOI  :  10.1186/s40364-023-00502-8

 received in 2023-03-19, accepted in 2023-05-12,  发布年份 2023

来源: Springer

【 摘 要 】

Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of plasma cells. Although therapeutic advances have been made to improve clinical outcomes and to prolong patients’ survival in the past two decades, MM remains largely incurable. Single-cell sequencing (SCS) is a powerful method to dissect the cellular and molecular landscape at single-cell resolution, instead of providing averaged results. The application of single-cell technologies promises to address outstanding questions in myeloma biology and has revolutionized our understanding of the inter- and intra-tumor heterogeneity, tumor microenvironment, and mechanisms of therapeutic resistance in MM. In this review, we summarize the recently developed SCS methodologies and latest MM research progress achieved by single-cell profiling, including information regarding the cancer and immune cell landscapes, tumor heterogeneities, underlying mechanisms and biomarkers associated with therapeutic response and resistance. We also discuss future directions of applying transformative SCS approaches with contribution to clinical translation.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_37_Article_IEq215.gif

Fig. 4

Fig. 2